Price Chart

Profile

Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its main product candidate is PCS499, which is intended for the treatment of Necrobiosis Lipoidica. The company was founded by David Young, Patrick Lin, Sian E. Bigora, Wendy Guy, and Chang Rung Chen on March 29, 2011 and is headquartered in Vero Beach, FL.
URL http://www.processapharmaceuticals.com
Investor Relations URL N/A
HQ State/Province Florida
Sector Health Care
Industry Pharmaceuticals
Next Earnings Release N/A
Last Earnings Release Nov. 13, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its main product candidate is PCS499, which is intended for the treatment of Necrobiosis Lipoidica. The company was founded by David Young, Patrick Lin, Sian E. Bigora, Wendy Guy, and Chang Rung Chen on March 29, 2011 and is headquartered in Vero Beach, FL.
URL http://www.processapharmaceuticals.com
Investor Relations URL N/A
HQ State/Province Florida
Sector Health Care
Industry Pharmaceuticals
Next Earnings Release N/A
Last Earnings Release Nov. 13, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A